Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surotomycin in Clostridium Difficile Infection
NCT01085591Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2010
- Primary completion
- Apr 2011
- Modality
- Cyclic Peptides, Peptide Conjugates, Antimicrobial Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of surotomycin in Clostridioides difficile infection (CDI) (3 arms), sponsored by Merck & Co. Primary endpoint: Clinical Response Outcome of Clostridium Difficile Infection Cure at Day 10. Started Apr 2010; status: completed.
02
Drugs
surotomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT01085591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01085591.